Search

Your search keyword '"B. Badie"' showing total 170 results
Start Over Author "B. Badie"
170 results on '"B. Badie"'

3. CLIN-IMMUNOTHERAPY/BIOLOGIC THERAPIES

Author

I. F. Pollack, R. I. Jakacki, L. Butterfield, H. Okada, Y. Chiba, N. Hashimoto, N. Kagawa, M. Kinoshita, N. Kijima, R. Hirayama, Y. Oji, A. Tsuboi, Y. Oka, H. Sugiyama, T. Yoshimine, R. D. Valle, S. Tejada, S. Inoges, M. A. Idoate, A. L. D. de Cerio, J. Espinos, J. Aristu, J. Gallego, J. P. Calvo, M. Bendandi, J. Zhu, C. Chen, A. Ravelo, E. Yu, R. Dhanda, I. D. Schnadig, L. Zhang, H. Fan, I. Zhang, X. Chen, H. Wang, A. Da Fonseca, B. Badie, L. H. Butterfield, R. L. Hamilton, A. H. Mintz, J. A. Engh, J. Drappatz, M. O. Lively, M. D. Chan, A. M. Salazar, D. M. Potter, E. G. Shaw, F. S. Lieberman, J. Wei, L.-Y. Kong, F. Wang, S. Xu, T. A. Doucette, S. D. Ferguson, Y. Yang, K. McEnery, K. Jethwa, O. Gjyshi, W. Qiao, F. F. Lang, G. Rao, G. N. Fuller, G. A. Calin, A. B. Heimberger, S. Yang, G. E. Archer, H. Miao, X. Cui, W. Xie, D. Snyder, A. J. Pretorian, A. Dechkovskaia, E. Reap, L. A. S. Perez, P. Norberg, R. Schmittling, D. A. Mitchell, J. H. Sampson, F. Lang, G. Calin, D. G. Walker, T. Crough, L. Beagley, C. Smith, L. Jones, R. Khanna, Y. Kanemura, M. Sumida, E. Yoshioka, A. Yamamoto, D. Kanematsu, Y. Matsumoto, H. Fukusumi, A. Takada, M. Nonaka, S. Nakajima, K. Mori, S. Goto, T. Kamigaki, R. Maekawa, T. Shofuda, S. Moriuchi, M. Yamasaki, J. T. Yeung, R. Hamilton, R. Jakacki, I. Pollack, S. Pellegatta, M. Eoli, C. Antozzi, S. Frigerio, M. G. Bruzzone, L. Cuppini, S. Nava, E. Anghileri, G. Cantini, E. Prodi, E. Ciusani, P. Ferroli, M. Saini, G. Broggi, R. Mantegazza, E. A. Parati, G. Finocchiaro, M. Hegde, A. Corder, K. K. Chow, M. Mukherjee, V. S. Brawley, H. E. Heslop, S. Gottschalk, E. Yvon, N. Ahmed, D. M. Gibo, W. Debinski, J. Bonomo, J. Rossmeisl, J. Robertson, P. Dickinson, M. E. Salacz, P. J. Camarata, M. Ots, J. McIntire, D. Lovick, G. Archer, D. Bigner, H. Friedman, D. Lally-Goss, B. Perry, J. Herndon, S. McGehee, R. McLendon, R. E. Coleman, J. Sampson, Z. Grada, T. Byrd, D. R. Shaffer, A. Ghazi, K. Schonfeld, G. Dotti, H. Heslop, W. Wels, M. L. Baker, J. M. Robbins, P. J. Dickinson, D. York, B. K. Sturges, B. Martin, R. J. Higgins, J. Bringas, K. Bankiewicz, H. E. Gruber, D. J. Jolly, A. Narayana, M. Mathew, R. Kannan, K. Madden, J. Golfinos, E. Parker, P. Ott, A. Pavlick, D. A. Bota, C. Pretto, P. Hantos, F. M. Hofman, T. C. Chen, J. A. Carrillo, V. E. Schijns, A. A. Stathopoulos, R. M. Prins, R. Everson, H. Soto, D. N. Lisiero, E. Young, L. M. Liau, A. Friedman, D. D. Bigner, D. Boczkowski, S. G. Gururangan, G. Grant, T. Driscoll, J. King, S. Nair, H. Fuchs, J. Kurtzberg, M. A. Shevtsov, A. V. Pozdnyakov, A. V. Kim, K. A. Samochernych, I. V. Guzhova, I. V. Romanova, B. A. Margulis, and W. A. Khachatryan

Subjects
Abstracts, Cancer Research, Oncology, business.industry, medicine.medical_treatment, Biologic therapies, Medicine, Neurology (clinical), Immunotherapy, Bioinformatics, business
Published
2012
Full Text
View/download PDF

4. IMMUNOTHERAPY

Author

M. J. Hickey, C. K. Malone, K. L. Erickson, L. E. Gerschenson, A. H. Lin, A. Inagaki, K. Hiraoka, N. Kasahara, B. Mueller, C. A. Kruse, S. Kong, B. Tyler, J. Zhou, B. S. Carter, H. Brem, R. P. Junghans, P. Sampath, R. K. Lai, L. D. Recht, D. A. Reardon, N. Paleologos, M. Groves, M. R. Rosenfeld, T. Davis, J. Green, A. Heimberger, J. Sampson, N. Hashimoto, A. Tsuboi, Y. Chiba, N. Kijima, Y. Oka, M. Kinoshita, N. Kagawa, Y. Fujimoto, H. Sugiyama, T. Yoshimine, S. M. Birks, M. Burnet, G. J. Pilkington, J. S. Yu, C. J. Wheeler, J. Rudnick, M. Mazer, H. Q. Wang, M. A. Nuno, J. E. Richardson, X. Fan, J. Ji, R. M. Chu, J. G. Bender, E. W. Hawkins, K. L. Black, S. Phuphanich, I. F. Pollack, R. I. Jakacki, L. H. Butterfield, H. Okada, M. A. Hunt, G. E. Pluhar, B. M. Andersen, J. L. Gallardo, C. O. Seiler, K. S. SantaCruz, J. R. Ohlfest, D. F. Bauer, L. S. Lamb, D. K. Harmon, X. Zheng, A. K. Romeo, G. Y. Gillespie, J. N. Parker, J. M. Markert, V. L. Jacobs, R. P. Landry, J. A. De Leo, J. E. Bromberg, J. Doorduijn, J. W. Baars, G. W. van Imhoff, R. Enting, M. J. van den Bent, K. A. Murphy, J. Bedi, A. Epstein, M. Olin, B. Andersen, L. Swier, J. Ohlfest, A. J. Litterman, D. M. Zellmer, E. A. Chiocca, L. K. Aguilar, E. Aguilar-Cordova, A. G. Manzanera, K. R. Harney, J. Portnow, B. Badie, M. Lesniak, S. Bell, A. Ray-Chaudhuri, B. Kaur, J. Hardcastle, R. Cavaliere, J. McGregor, S. Lo, A. Chakarvarti, J. Grecula, H. Newton, T. W. Trask, D. S. Baskin, P. Z. New, J. Zeng, A. P. See, J. Phallen, Z. Belcaid, N. Durham, C. Meyer, E. Albesiano, G. Pradilla, E. Ford, H. Hammers, P. T. Tran, D. Pardoll, C. G. Drake, M. Lim, A. Ghazi, A. Ashoori, P. Hanley, V. Salsman, D. R. Schaffer, Z. Grada, Y. Kew, S. Z. Powell, R. Grossman, M. E. Scheurer, A. M. Leen, C. M. Rooney, C. M. Bollard, H. E. Heslop, S. Gottschalk, N. Ahmed, J. Hu, C. Patil, M. Nuno, C. Wheeler, R. Chu, K. Black, J. Yu, A. Marabelle, H. Kohrt, J. Brody, R. Luong, V. Tse, R. Levy, Y. M. Li, H. Jun, M. Shahryar, V. A. Daniel, H. A. Walter, I. Thaipisuttikul, E. Avila, D. A. Mitchell, G. E. Archer, H. S. Friedman, J. E. Herndon, D. D. Bigner, J. H. Sampson, L. A. Johnson, S. K. Nair, R. Schmittling, E. Reap, J. P. Knisely, H. Kluger, J. Flanigan, M. Sznol, J. B. Yu, V. L. Chiang, R. M. Prins, W. Kim, H. Soto, D. N. Lisiero, and L. M. Liau

Subjects
Abstracts, Cancer Research, Oncology, Neurology (clinical)
Published
2011
Full Text
View/download PDF

5. Immunology Research

Author

A. Wu, J. Wei, L.-Y. Kong, Y. Wang, W. Priebe, R. Sawaya, A. B. Heimberger, A. Heimberger, T. Doucette, J. Yang, G. Rao, S. Shimato, L. M. Meier, M. Castelli, P. Canoll, M. Asslaber, J. N. Bruce, D. E. Anderson, R. C. Anderson, E. W. Mahlum, R. B. Jenkins, G. Kohanbash, A. H. Mintz, K. McKaveney, H. A. McDonald, J. R. Ohlfest, H. Okada, M. Fujita, L. Zhang, W. Liu, D. Alizadeh, D. Zhao, O. Farrukh, B. Badie, B. Raychaudhuri, S. Pellegatta, G. Cantini, F. Pisati, L. Cuppini, G. Finocchiaro, E. Albesiano, J. E. Han, A. See, C. Jackson, M. Lim, K. Nag, J. White, T. Sippel, M. Klaassen, V. Tsvankin, A. Waziri, S. Mittal, I. M. Zitron, W. J. Kupsky, B. Alkonyi, S. Sood, and C. Juhasz

Subjects
Cancer Research, Oncology, Neurology (clinical)
Published
2010
Full Text
View/download PDF

6. Immunotherapy

Author

M. Fujita, G. Kohanbash, H. A. McDonald, L. Delamarre, S. A. Decker, J. R. Ohlfest, H. Okada, P. Kalinski, R. Ueda, A. Hoji, T. E. Donegan, A. H. Mintz, J. A. Engh, D. L. Bartlett, C. K. Brown, H. Zeh, M. P. Holtzman, T. A. Reinhart, T. L. Whiteside, L. H. Butterfield, R. L. Hamilton, D. M. Potter, I. F. Pollack, A. M. Salazar, F. S. Lieberman, M. R. Olin, B. M. Andersen, P. T. Grogan, M. Hunt, F. E. Popescu, Z. L. Xiong, C. Seiler, C. L. Forster, K. S. SantaCruz, W. Chen, B. R. Blazar, J. Hu, C. J. Wheeler, S. Phuphanich, J. Rudnick, M. Nuno, N. Serrano, J. Dantis, J. Richardson, M. Mazer, H. Q. Wang, R. Chu, K. L. Black, J. Yu, Y. M. Li, D. A. Vallera, W. A. Hall, J. D. Rudnick, R. M. Chu, H. Wang, J. S. Yu, I. Yang, S. Han, T. Tihan, M. Wrensch, A. T. Parsa, M. A. Hunt, J. L. Gallardo, G. E. Pluhar, C. E. Brown, R. Starr, C. Martinez, J. Bading, J. A. Ressler, B. Badie, M. C. Jensen, R. P. Glick, A. Ksendzovsky, R. Zengou, P. Polak, V. Simonini, T. Lichtor, D. Feinstein, K. K. Chow, N. Ahmed, V. S. Salsman, Y. Kew, S. Powell, R. Grossman, H. E. Heslop, S. Gottschalk, F. H. Barnett, V. Marchetti, M. Wang, A. Johnson, L. Scheppke, R. Jacobson, G. Nemerow, M. Friedlander, V. Salsman, A. M. Leen, C. M. Bollard, C. Rooney, P. Z. New, B. Salvoldo, and H. Heslop

Subjects
Cancer Research, Oncology, Neurology (clinical)
Published
2010
Full Text
View/download PDF

7. Tuberculosis Diagnosed after Major Hepatectomy for Suspected Malignancy

Author

S. Dobos, Th. Ballet, S. Landen, V. Delugeau, B. Badie, R. Kessler, and M. Costache

Subjects
Male, medicine.medical_specialty, Pathology, Tuberculosis, medicine.medical_treatment, Adenocarcinoma, Anticancer chemotherapy, Metastasis, Diagnosis, Differential, Lesion, Suspected malignancy, Tuberculosis, Hepatic, medicine, Hepatectomy, Humans, Aged, business.industry, Liver Neoplasms, General Medicine, medicine.disease, Colonic Neoplasms, Surgery, Radiology, Differential diagnosis, medicine.symptom, business, Major hepatectomy
Abstract

A patient with a history of surgery and adjuvant chemotherapy 2’/2 years previously for Dukes C colonic adenocarcinoma was diagnosed with a focal liver lesion on follow-up examinations. Ultrasound and computed tomography scan revealed a 3.8 cm soft tissue mass. Positron emission tomography scan showed intense uptake, corroborating the diagnosis of a colonic liver metastasis. Major hepatectomy was performed but pathology revealed that the lesion was in fact a benign tuberculosis pseudo-tumour.In developed countries liver tuberculosis remains extremely rare, particularly the macronodular form. The diagnosis is often made only after hepatectomy for suspected malignancy. The increasing use of potent anticancer chemotherapy may favour the reactivation of quiescent tuberculosis, posing a difficult differential diagnosis with liver metastases.

Published
2010
Full Text
View/download PDF

8. PRELIMINARY RESULTS OF A PROSPECTIVE FEASIBILITY PILOT STUDY OF 'GEMPOX' (GEMCITABINE, OXALIPLATIN, AND PACLITAXEL) IN PEDIATRIC AND ADULT PATIENTS WITH REFRACTORY OR RECURRENT CENTRAL NERVOUS SYSTEM (CNS) GERM CELL TUMORS (GCT): THE INTERNATIONAL CNS GCT CONSORTIUM TRIAL, CNS GCT-4

Author

J. L. Finlay, Y. Liu, K. Haley, A. Erdreich-Epstein, T. Rushing, J. Grimm, K. E. Wong, E. Kiehna, M. D. Krieger, F. Gilles, B. Badie, M. D'Apuzzo, and G. Dhall

Subjects
Cancer Research, medicine.medical_specialty, Germinoma, business.industry, medicine.disease, Gastroenterology, Chemotherapy regimen, Minimal residual disease, Gemcitabine, Surgery, Oxaliplatin, abstracts, Regimen, Oncology, Internal medicine, medicine, Neurology (clinical), Germ cell tumors, business, Progressive disease, medicine.drug
Abstract

BACKGROUND: The optimal management of patients with recurrent CNS GCT, especially those with non-germinomatous (mixed malignant) GCT (MMGCT), remains unclear. Preliminary results are presented on the response rate, toxicity and early outcomes of a re-induction regimen of gemcitabine, oxaliplatin and paclitaxel (GEMPOX) administered, in responsive patients, prior to myeloablative chemotherapy and autologous hematopoietic cell rescue (HDCx + AuHCR). METHODS: Since December 2004, 13 recurrent or refractory patients (12 MMGCT, 1 germinoma; 12 males; mean age 16.5 years, range 7-34 years) have been treated with up to 4 cycles of gemcitabine (800 mg/m2), oxaliplatin (100 mg/m2) and paclitaxel (170 mg/m2), administered on one day at 14 days intervals. RESULTS: Of 13 patients, five were treated on a preceding feasibility pilot with 1-3 cycles of GEMPOX, and seven have been formally enrolled on an ongoing prospective multi-center trial. Six patients achieved complete remissions (tumor marker and/or imaging studies), five achieved partial remissions and two developed progressive disease (PD) while on GEMPOX; one patient with PD after 1 cycle had pathologically confirmed malignant transformation to pure embryonal rhabdomyosarcoma.; the second patient, with pure pineal choriocarcinoma, progressed following the second cycle of GEMPOX. Eleven of the 13 patents subsequently underwent HDCx + AuHCR. Six of them subsequently received irradiation. Transient hepatotoxicity and pancytopenia were the most commonly observed toxicities. Other toxicities included: paclitaxel anaphylaxis (1), transient encephalopathy (1), peripheral neuropathy (1), hyperesthesia (4), mucositis (2) and electrolyte imbalances (3). Four of the 12 patients with MMGCT continue alive and disease-free for 8+ , 10+ , 14+ and 16+ months since discontinuation of all therapy. One patient (with pure yolk sac tumor) relapsed in a loco-regional extra-CNS location (cavernous and ethmoid/sphenoid sinuses) and remains alive with progressive disease on therapy now 12+ months post-HDCx + AuHCR. CONCLUSIONS: GEMPOX appears to be an effective re-induction regimen for patients with recurrent CNS MMGCT, with acceptable toxicities. The ongoing multi-center, international trial should confirm this and demonstrate the contribution of GEMPOX towards improved survival when followed by HDCx + AuHCR with or without further irradiation, in the setting of minimal residual disease. SECONDARY CATEGORY: Pediatrics.

Published
2014

9. Diplomacy of Connivance

Author

B. Badie and B. Badie

Subjects
World politics, Diplomacy, International relations
Abstract

The status quo of the modern world order, a diplomatic entente best characterized as'connivance diplomacy,'is limited in its performances, defensive of its privileges, midway between competition and cooperation. It is examined here through its history, its functions, and its failures.

Published
2012

10. Tumour cell dispersion by the ultrasonic aspirator during brain tumour resection

Author

J. K. Preston, J. Masciopinto, B. Badie, and M. S. Salamat

Subjects
Pathology, medicine.medical_specialty, business.industry, Cell, Tumor resection, Neoplasm Seeding, General Medicine, Aspirator, Ultrasonic aspirator, medicine.anatomical_structure, Neoplasm Recurrence, medicine, Surgery, Ultrasonic sensor, Neurology (clinical), business, Brain neoplasm
Abstract

Ultrasonic aspirators are commonly used to resect brain tumours because they allow safe, rapid and accurate removal of diseased tissue. Since ultrasonic aspirators generate a spray of aerosolized irrigating fluid around the instrument tip, we questioned whether this spray might contain viable tumours cells that could contribute to intraoperative spread of tumour fragments. To test this hypothesis, we collected the spray produced during the resection of nine brain tumours with an ultrasonic aspirator and semi-quantitatively analysed it for tumour presence. The aerosolized irrigation fluid was found to contain intact tumour cells or clumps of tumour cells in all nine instances, and there was a trend of increasing tumour cell dispersion with increasing ultrasonic aspiration times. Further examination is required to determine if this intraoperative dispersion of apparently viable tumour fragments contributes to local neoplasm recurrence.

Published
1999
Full Text
View/download PDF

11. LAB-IMMUNOLOGY RESEARCH

Author

M. Fujita, R. Zhang, S. Nakata, K. Kuzushima, D. A. Wainwright, I. V. Balyasnikova, B. Auffinger, A. U. Ahmed, Y. Han, M. S. Lesniak, A. Knight, H. Arnouk, G. Y. Gillespie, W. Britt, Y. Su, M. W. Lowdell, L. S. Lamb, J. Wang, L. Leiss, B. D. Choi, C.-T. Kuan, M. Cai, D. D. Bigner, J. H. Sampson, I. Shibahara, R. Saito, M. Kanamori, Y. Sonoda, T. Kumabe, T. Kikuchi, T. So, N. Ishii, T. Tominaga, L. Zhang, H. Wang, I. Zhang, X. Chen, A. Da Fonseca, H. Fan, B. Badie, E. J. Sayour, P. McLendon, R. Reynolds, R. McLendon, D. A. Mitchell, L. Sanchez-Perez, C. Pham, D. Snyder, W. Xie, X. Cui, M. J. McConnell, K. W. Broadley, K. Farrand, A. Authier, J. H. Brown, M. Hunn, I. Hermans, G. Cantini, F. Pisati, S. Pessina, G. Finocchiaro, S. Pellegatta, J. T. Yeung, R. Hamilton, I. Pollack, R. Jakacki, H. Okada, B. Choi, R. J. Schmittling, C. Flores, L. Johnson, G. A. Archer, B. Raychaudhuri, P. Rayman, P. Huang, J. Ireland, S. Donnola, D. Hamburdzumyan, J. Finke, M. A. Vogelbaum, K. Batich, E. Reap, G. Archer, J. Sampson, D. Mitchell, A. M. Martin, C. Nirschl, M. Polanczyk, K. J. Cohen, D. M. Pardoll, C. G. Drake, M. Lim, W. C. Rutledge, J. Kong, J. Gao, D. A. Gutman, L. A. Cooper, C. Chisolm, L. Scarpace, T. Mikkelsen, J. H. Saltz, C. S. Moreno, D. J. Brat, R. G. Everson, D. N. Lisiero, H. Soto, L. M. Liau, R. M. Prins, G. C. Gonzalez, M. Chae, T. E. Peterson, I. F. Parney, and A. J. Johnson

Subjects
Cancer Research, Engineering, medicine.medical_specialty, Abstracts, Oncology, business.industry, medicine, Medical physics, Neurology (clinical), business
Published
2012

12. CLIN-NEURO/MEDICAL ONCOLOGY

Author

F. Girardi, C. Braun, Dennis C. Shrieve, Wei Chen, D. Kita, M. F. Fanelli, David Schiff, Sunyoung Ahn, Elizabeth Vera-Bolanos, J. Carrasquillo, S. Singer, James G. Herman, C. Bosa, Julia Selfridge, V. Tohidi, B.-A. Millar, M. Benavides, M. I. D. L. Fuente, Phioanh L. Nghiemphu, Kristin R. Swanson, John P. Kirkpatrick, Jonathan P.S. Knisely, Jörg C. Tonn, Kenneth Aldape, J. C. Streeter, R. Ruda, Seung Hong Choi, R. Curry, J. Yu, Ryo Nishikawa, E. Garoufalis, A. H. Friedman, Kurt A. Jaeckle, W. Zhang, Maryam Fouladi, Y. Odia, Arthur P. Chou, S. Sahebjam, E. Pentsova, Luis Souhami, Y. Yuan, F. N. Santos, C. Mesia, H. Friedman, Jennifer Linn, J. E. Adair, Yong Hwy Kim, Athanasios P. Kyritsis, Zvi Ram, M. G. Muhonen, Tracy T. Batchelor, Alissa A. Thomas, Stuart A. Grossman, M. Nasseri, Pedro Pérez Segura, S. Lacey, S. D. Bell, Helen A. Shih, E. Bit-Ivan, Timothy A. Chan, H. Pentsova, H. Wilson, Fumiko Shimizu, M. Forbes, L. Randolph, S. Kim, Amit Bhatt, Sabina Eigenbrod, T. Seigal, P. Dall'Occa, F. McSherry, R. M. Green, Michael D. Prados, Camilo E. Fadul, A. Guevarra, J.-Y. Han, Guido Reifenberger, E. Franceschi, D. Sageser, Jennie Taylor, Kevin Petrecca, M. K. Nicholas, Teresa Ribalta, Morris D. Groves, J.-Y. Blay, B. C. Beard, C. F. La, A. A. da Costa, K. Murillo-Medina, W. Pfisterer, R. Chu, Nan Lin, M. Ermani, A. J. Neuwelt, Samuel T. Chao, T. Ranjan, W. Taki, Hendrik Janssen, R. Agati, A. Mahta, T. N. Kreisl, E. Perez, J. Fuster, B. D. Fu, David M. Peereboom, N. Gresa-Arribas, Georg Widhalm, M. D'Apuzzo, J. Steinbach, Tom Mikkelsen, Michael Platten, R. Poggi, Sandra Ictech, I. Craven, A. Raghunathan, John B. Fiveash, N. L. Jansen, Rupert Egensperger, B. Badie, S. Medrano, Chul-Kee Park, K. Wong, Tae Min Kim, M. Bartolotti, M. Alejandro, T. Rosser, H.-P. Kiem, Marie-Christine Guiot, S. Gonzalez, J. Ljubimova, T. Furuta, J. Herndon, J. Finlay, Vivian Tabar, M. Hadjivassiliou, Christine Marosi, D. Hammoud, K. Black, S. K. Anderson, F. Bach, Gregory N. Fuller, N. Kased, S. Shpigel, Gianluca Marucci, Michael A. Vogelbaum, S. Bluml, J. Joo, M. D. Groves, X. Ye, Adam L. Cohen, J. A. Butman, M. D. Prados, X. Perez-Martin, R. Sharma, G. Colon-Otero, Richard M. Green, Paul D. Brown, Cornelia Sax, Robert J. Weil, J. Connelly, S. Burri, M. R. Welch, Marc K. Rosenblum, Minesh P. Mehta, Shlomit Yust-Katz, J. Canellas, Ulrich Bogdahn, S. Liker, P. U. Kumthekar, F. Gilles, M. Brock, Aaron T. Wild, A. Guerrero-Maldonado, Janet M. Bruner, A. Balmanoukian, E. Kitzweger, B. Schuknecht, Ayman I. Omar, J. Sampson, R. F. Del Maestro, W. Hruby, Niklas Thon, S. Zhao, F. Aboul-Enein, L. M. Alderson, J. McClain, J. Rudnick, J. Dorr, Vinay K. Puduvalli, Sonia Partap, Y. Hayashi, A. Kessinger, N. A. Shonka, T. Minamoto, D. Z. Lee, L. G. Berriel, T. Xie, J. Shih, J. S. Bubalo, Oscar Lin, J. E. Herndon, Michael Glantz, A. Gupta, H. Sabit, H. Heinrichs, Hans A. Kretzschmar, A. Asher, T. M. Bhavsar, A. Coan, V. A. Levin, M. Landeros, A. K. Choucair, D. Garbossa, G. Stockhammer, Jian Campian, C. J. Vecht, C. Ausch, Linda M. Liau, H. I. Farhat, M. Richards, H. I. Robins, R. Chaudhary, Agnieszka Korfel, Marta Penas-Prado, A. Jensen, I. Lolli, Amar J. Gajjar, K. Papsdorf, L. DeAngelis, Kathryn Beal, L. Phishniak, J. Joyce, Arnab Chakravarti, J. J. Vredenburgh, C. Dealis, A. F. Campos-Gines, Peter Hau, J.-I. Hamada, R. A. Gilbert, T. J. Kaley, Eric T. Wong, Ian F. Pollack, T. Gajewski, A. C. Levy, L. R. Bressler, X. Chen, C. Bernadette, O. Etxaniz, N. Antony, Birgit Flechl, D. Levacic, Byung Se Choi, J. I. Stenner, F. Pinto, Sandra K. Johnston, M. M. Mrugala, David Roberge, M. Wang, P. J. Anderson, H. A. Fine, M. J. Glantz, Alfred Yung, L. Alderson, M. Chamberlain, R. Naor, Jaume Capellades, Se-Hoon Lee, D. G. Brackman, Nathalie Jansen, T. Synold, Terri S. Armstrong, J. Pichler, X.-T. Kong, T. Cloughesy, P. Frankel, R. Valdez-Vazquez, Mathias Kunz, J. Dalmau, A. Baldock, Stewart Goldman, K. Rizzo, M. Nakada, Christoph Meisner, Ryan Merrell, C. Bomprezzi, Tomokazu Aoki, M. R. Gilbert, Jason K. Rockhill, Benjamin Ellezam, C. Sebastian, O. Arrieta, N. Wu, M. Magistrello, T. Patel, Adelheid Wöhrer, M. Sabel, F. Bokstein, V. Gomez-Molinar, S. Yovino, A. Kheder, Gaspar Reynes, R. Packer, M. Ronellenfitsch, Sasan Karimi, David Piccioni, J. M. Stachnik, C. Sebesta, Ryan Shanley, L. T. Chinen, H.-S. Gwak, E. A. Woyshner, D. Reuter, S. Bekker, K. Hunter, B. Haghighi, G. Poepperl, M. C. Chamberlain, W. Massey, M. A. Hamza, R. Cavaliere, Sichen Li, Daniela A. Bota, S. Spiegl-Kreinecker, G. Tatzreiter, Sigmund Hsu, M. Westphal, T. Pietsch, P. D. Barnes, C. Arango, G. Cervantes-Sanchez, C. Grommes, W. Brick, Vera Graute, M. P. Gabay, L. Bertero, Friedrich W. Kreth, F. M. Iwamoto, D. T. Blumenthal, M. Matsutani, K. B. Peters, S. F. Shakur, E. Flanagan, H. T. Kim, M. Simon, Michael Ackerl, Nadia N. Laack, J. Portnow, R. Ruckser, T. F. Cloughesy, H. Wayne Slone, A. A. Erazo-Valle-Solis, Karin Dieckmann, J. Baerhing, R. Soffietti, N. Laperriere, M. J. Gil, R. Fisher, Thierry Muanza, Reema R. Mody, W. Kim, L. Droms, Fabio M. Iwamoto, J. Grimm, Robert B. Jenkins, M. R. Aizenberg, E. Lipp, M. J. Taphoorn, V. Garcia-Navarro, J. H. Suh, Peter Bartenstein, E. Bourekas, Brett Theeler, W. G. Watkin, R. M. Tyson, Mira Zurayk, D. Alexandru, N. Uchiyam, J. Gilreath, A. J. Ramiro, R. Rockne, R. Naruse, M. Krieger, A. Kloet, Petr Kavan, E. Jaffe, D. A. Reardon, Jochen Herms, A. Willson, H. Zwinkels, M. Faedi, A. Moreno-Aspitia, J. Vredenburgh, Herbert H. Engelhard, C. Bridge, Paul W. Sperduto, H. Yoo, P. Friedman, N. Letarte, Tetsuya Ueba, Lisa M. DeAngelis, C. Nolan, Michael Weller, H. Colman, Jürgen Lutz, H. Ian Robins, J. McGregor, Pankaj Jalan, Joseph Landolfi, M. Di Battista, Bogdana Suchorska, Manuela Caroli, G. Nikkhah, A. Leibetseder, K. Aboody, V. Liu, Albert Lai, Yoshiki Arakawa, Kazuhiko Nozaki, G. Dhall, Kenneth R. Hess, Oscar Gallego, A. Naomi, A. Pace, T. M. Nguyen, K. Kawakami, K. DeBraganca, A. A. Brandes, V. K. Puduvalli, Lakshmi Nayak, Charles A. Conrad, Laurie E. Gaspar, P. J. Flynn, S. Ruiz-Gonzalez, Carmen Balana, J. Lange, T. Kaley, Vijay Pandav, J. Herrada, Eugenia Verger, S. Honigschnabel, M. Chen, C. A. Bridge, Yu Jung Kim, Mary Jo T. Necesito-Reyes, Bettina Hentschel, Victor A. Levin, J. Hu, K. Hoang-Xuan, Chae-Yong Kim, W. Sherman, L. Armbruster, T. Yun, C. Carapella, E. L. Diamond, A. Mahapatra, Warren P. Mason, X. Luo, R. C. Rockne, S. G. Crasto, L. Bailey, K. Sanghee, Matthias Preusser, R. Mathew, Jaclyn Wu, D. White, Susumu Miyamoto, A. Omuro, A. Desjardins, P.H. Gutin, J. S. Lee, Andrew D. Trister, Maxwell Lewis Neal, W. Zaky, A. L. Sumrall, C. M. Sperduto, A. L. Baldock, S. Phuphanich, J. Sul, S. H. Shin, E. A. Neuwelt, Heinrich Elinzano, C. Huang, H. S. Friedman, Laura Guyman, Sean Grimm, C. Sanchez, H. Newton, G. Oberhauser, Chunyue Yin, Wolfgang Wick, Caterina Giannini, Veronica Chiang, C. LaFougere, P. Metellus, A. Krauthammer, M. Kinoshita, J. Sheehan, Miguel J. Gil, E. Trevisan, J. Raizer, Shin-Ichi Miyatake, A. Olch, Jin Wook Kim, John L. Villano, Patricia Sneed, Brian P. O'Neill, A. Sahgal, Il Han Kim, A. Brickhouse, K. Herath, C. Zoccoli, M. J. van den Bent, T. Tsukahara, M. Heaney, B. Hassanzadeh, J. Quan, David R. Macdonald, Percy Ivy, D. Liue, John H. Suh, K. Miyashita, T. J. Fraum, W. A. Yung, I. Melguizo-Gavilanes, Maciej M. Mrugala, Matthew J. Matasar, and P. Garciarena

Subjects
Cancer Research, medicine.medical_specialty, Abstracts, Oncology, business.industry, medicine, Medical physics, Neurology (clinical), business
Published
2012

13. Acute Sequelae of Stereotactic Radiosurgery

Author

T.S. Hong, W.A. Tomé, Z. Yuan, L. Hayes, B. Badie, M.P. Mehta, and R. Rao

Subjects
medicine.medical_specialty, business.industry, medicine.medical_treatment, medicine, macromolecular substances, Radiology, business, Radiosurgery
Abstract

Background: Over the last decade, the application of stereotactic radiosurgery has expanded significantly for several clinical indications including benign and malignant tumors, vascular malformations

Published
2004
Full Text
View/download PDF

15. [Extra-oral implants: surgical procedures]

Author

M, Brix, B, Badie-Modiri, and P, Delcampe

Subjects
Time Factors, Maxillofacial Prosthesis, Bone Screws, Suture Techniques, Prostheses and Implants, Nose, Prosthesis Design, Prosthesis Implantation, Treatment Outcome, Osseointegration, Prosthesis Fitting, Humans, Ear, External, Bone Plates
Abstract

The different extra-oral implant systems (screw and plate fixation) are not compatible. Rigorous surgical procedure (detailed and illustrated here) is mandatory to obtain the best implant osseointegration and epithesis loading 3 months later. Besides surgical procedure, careful bone and peri-abutment suture are required for success.

Published
2001

16. [Extra-oral implants: principal areas of implantation]

Author

B, Badie-Modiri and P, Kaplanski

Subjects
Maxillofacial Prosthesis, Osseointegration, Risk Factors, Skull, Maxilla, Humans, Temporal Bone, Nasal Bone, Prostheses and Implants, Prosthesis Design, Orbit, Orbital Implants
Abstract

The success of extra-oral implants raises a certain number of technical and medical problems. Among these, the anatomy of the implant zone and bone quality are determining factors for osteointegration of the implants. We describe the principal zones of implantation detailing the risks involved in each area.

Published
2001

17. Legitimacy, Sociology of

Author

B. Badie

Subjects
Power (social and political), media_common.quotation_subject, Political science, Historical sociology, Comparative politics, Social science, Dimension (data warehouse), Institution building, Legitimacy, Obedience, media_common, Law and economics
Abstract

Legitimacy is a Key concept of political science, sice it defines how individuals accept a power and conceive their obedience as a just commitment. The Weberian sociology provides us with the main and well-known reference for building a sociology of legitimization. But the sociology of legitimacy deals also with the strategic dimension. How do the power-holders strive to make their commands accepted as such? How do they manipulate the legitimizing formulas? Finally, this sociology becomes aware of the historical dimensions of legitimacy, and thus opens to comparative politics (regarding the institution building process), to the sociology of change and of the international arena.

Published
2001
Full Text
View/download PDF

18. Use of titanium mesh for reconstruction of large anterior cranial base defects

Author

B, Badie, J K, Preston, and G K, Hartig

Subjects
Adult, Male, Skull Base, Titanium, Skull, Humans, Female, Middle Aged, Plastic Surgery Procedures, Surgical Mesh, Aged
Abstract

The authors evaluated the role of titanium mesh used in combination with vascularized pericranium to provide rigid support during reconstruction of anterior skull base defects. Thirteen patients with large anterior skull base defects caused by tumor invasion or traumatic injury involving the cribriform plate, orbital roof, and planum sphenoidale were included in the study. The reconstruction technique involved placement of titanium mesh between two layers of continuous vascularized pericranium. Surgical glue and routine lumbar cerebrospinal fluid (CSF) drainage were not used in any patient. At a mean postoperative follow-up time of 22 months (range 8-39 months), none of the patients had developed infection or meningocele. Postoperative CSF rhinorrhea occurred in two patients with extensive dural defects, which resolved with temporary lumbar drainage. Use of titanium mesh and a two-layer vascularized pericranial graft is a safe, reproducible, and feasible method for reconstructing the anterior skull base. Patients with large dural defects may need temporary CSF diversion to avoid postoperative fistula formation.

Published
2000

19. Tumour cell dispersion by the ultrasonic aspirator during brain tumour resection

Author

J K, Preston, J, Masciopinto, M S, Salamat, and B, Badie

Subjects
Neoplasm Seeding, Brain Neoplasms, Ultrasonic Therapy, Humans, Neoplasm Recurrence, Local, Suction
Abstract

Ultrasonic aspirators are commonly used to resect brain tumours because they allow safe, rapid and accurate removal of diseased tissue. Since ultrasonic aspirators generate a spray of aerosolized irrigating fluid around the instrument tip, we questioned whether this spray might contain viable tumours cells that could contribute to intraoperative spread of tumour fragments. To test this hypothesis, we collected the spray produced during the resection of nine brain tumours with an ultrasonic aspirator and semi-quantitatively analysed it for tumour presence. The aerosolized irrigation fluid was found to contain intact tumour cells or clumps of tumour cells in all nine instances, and there was a trend of increasing tumour cell dispersion with increasing ultrasonic aspiration times. Further examination is required to determine if this intraoperative dispersion of apparently viable tumour fragments contributes to local neoplasm recurrence.

Published
2000

20. [Sebaceus nevus of Jadassohn. Apropos of 62 surgically treated cases and review of the literature]

Author

D, Labbé, B, Badie Modiri, and F, Petit

Subjects
Male, Hyperplasia, Skin Neoplasms, Adolescent, Hamartoma, Puberty, Infant, Newborn, Infant, Skin Pigmentation, Skin Diseases, Sebaceous Glands, Apocrine Glands, Cell Transformation, Neoplastic, Scalp Dermatoses, Carcinoma, Basal Cell, Child, Preschool, Humans, Female, Epidermis, Child, Facial Dermatoses
Abstract

The analysis of 62 cases of nevus sebaceus of Jadassohn and the study of the literature allows to define the clinical and histo-pathologic features of this benign tumor. The massive development of sebaceous glands, papillomatous epidermal hyperplasia, and maturation of apocrines glands, are present in a considerable number of cases. The lesions occurred on the scalp, face, auricular area and neck and are usually present at birth as a yellowish orange area. At puberty, the lesion becomes yellow to dark-brown and is verrucoid and micronodular. Almost all are hair-deficit nevi, and the final stage is the development of secondary tumors of the skin within the lesion. The risk of degeneration in basal-cell carcinoma justifies systematic surgical treatment.

Published
1999

22. [Mandibular reconstruction of gunshot wounds by progressive bone distraction. Report of five cases]

Author

D, Labbé, B, Badie Modiri, E, Kaluzinski, and J F, Compère

Subjects
Adult, Radiography, Treatment Outcome, Bone Lengthening, Humans, Wounds, Gunshot, Middle Aged, Facial Injuries, Mandibular Injuries, Aged
Abstract

Five adult patients with gunshot wound defect underwent bilateral mandibular lengthening by an extraoral device. All patients presented with interrupting mandibular defect of 50 to 100 mm. Distraction of bone fragments led to mandibular reconstruction without bone grafting and simultaneous expansion of soft tissues, avoiding free or pedicled myocutaneous flaps for soft tissue reconstruction of the lower third of the face. Mandibular distraction also recreated the alveolar ridge with its attached mucosa which is equivalent to the gingiva. It can be used for dental rehabilitation by osseointegrated implants. Avoiding the morbidity and functional problems of classical flaps, mandibular distraction accelerates facial reconstruction, and social reinsertion of these patients.

Published
1998

23. Adenovirus-mediated p53 gene delivery potentiates the radiation-induced growth inhibition of experimental brain tumors

Author

B, Badie, M H, Kramar, R, Lau, D A, Boothman, J S, Economou, and K L, Black

Subjects
Radiation Injuries, Experimental, Brain Neoplasms, Cell Cycle, Gene Transfer Techniques, Tumor Cells, Cultured, Animals, Humans, Gliosarcoma, Tumor Suppressor Protein p53, Adenoviridae, Rats
Abstract

Patients with malignant gliomas continue to have very poor prognosis even after surgical resection, radiation and chemotherapy. Because these tumors often have alterations in the p53 tumor suppressor gene, which plays a key role in the cellular response to DNA damaging agents, we investigated the role of p53 gene therapy in conjunction with ionizing radiation in a rat brain tumor model. Exposure of cultured rat 9L gliosarcoma cells, which contain a mutant p53 gene, to a recombinant adenovirus-vector bearing the wild-type p53 gene (Adp53), induced apoptosis within 24 hours. Although ionizing radiation had no additional effect on apoptosis within this time frame, it caused G1 arrest in non-apoptotic cells after Adp53 therapy. In contrast, wild-type 9L cells demonstrated little G1 arrest after X-irradiation. When animals bearing brain tumors were irradiated after intratumoral Adp53 injections, more than 85% reduction in tumor size was noted. Moreover, the group of rats receiving both radiation and Adp53 therapy had a significant increase in survival as compared to animals receiving either therapy alone. These results support the use of p53 gene therapy as an adjunct to radiation in treatment of malignant brain tumors.

Published
1998

25. Cosmetic reconstruction of temporal defect following pterional [corrected] craniotomy

Author

B, Badie

Subjects
Skull, Humans, Temporal Bone, Temporal Muscle, Surgery, Plastic, Craniotomy, Surgical Flaps
Abstract

Depression of the temporal fossa that is often caused by atrophy of the temporalis muscle or superficial temporal fat pad may be an unavoidable defect following pterional craniotomy. Various techniques have been previously described to correct this disfiguring defect. Most techniques, however, require drilling holes into the cranium or the synthetic grafts for attachment of the temporalis muscle.A simple method is described by which a temporal fossa depression is repaired with methylmethacrylate bone cement and a new superior temporal line is created for attachment of the temporalis muscle without the need to drill suture holes into the acrylic or the cranium.The technique described has been used on several patients with excellent cosmetic outcome.

Published
1996

28. Transport and metabolism of glucose by renal proximal tubular cells in primary culture

Author

Leon G. Fine, N. Mikhail, A. G. Lowe, L. M. Sakhrani, B. Badie-Dezfooly, Mary Taub, and W. Trizna

Subjects
Methylglycosides, education.field_of_study, Physiology, Phlorizin, Population, Glucose transporter, Biological Transport, Active, Methylglucosides, Metabolism, Carbohydrate, Pentose phosphate pathway, Biology, Membrane transport, Kidney Tubules, Proximal, Kinetics, chemistry.chemical_compound, Glucose, chemistry, Biochemistry, Animals, Rabbits, education, Energy source, Cells, Cultured
Abstract

A highly purified suspension of rabbit proximal tubules was cultured in a hormone-supplemented serum-free medium. This primary culture yielded a homogeneous population of cells that demonstrated functional and morphological polarity in mono-layers. The characteristics of the Na-dependent glucose transporter in the luminal membrane were studied by measuring the uptake of alpha-methylglucoside (AMG). The kinetics of Na-dependent AMG uptake were consistent with a single saturable system with an apparent Km of 0.8 mM and Jmax of 0.14 nmol X mg-1 X min-1. AMG permeability was 0.10 microliter X mg-1 X min-1. Uptake was inhibited 95% by 0.1 mM phlorizin and by removal of sodium. The stoichiometry of Na/glucose interaction with the carrier was 2:1. These characteristics are typical of the characteristics described for the late proximal tubule. To examine whether the glucose that enters the cell across the luminal membrane is incorporated into the metabolic pool of the cell, we studied the oxidation of [14C]glucose to 14CO2 in the absence and presence of phlorizin. Significant decarboxylation of [1-14C]glucose and [6-14C]glucose was observed, consistent with the existence of aerobic metabolism and a hexose monophosphate shunt. In the presence of 0.1 mM phlorizin, uptake and oxidation of D-glucose were inhibited to an identical degree, suggesting that luminal uptake is a rate-limiting step in the oxidation of glucose by these proximal tubular cells. These studies indicate that proximal tubular cells in primary culture utilize glucose as an energy source and that the glucose derived from transport across the luminal membrane is incorporated into the metabolic pool of the cell.

Published
1984
Full Text
View/download PDF

31. Political Parties

Author

PANEBIANCO, ANGELO, B. Badie, D. Berg-Schlosser, L. Morlino, and Panebianco, A.

Subjects
partito scienza politica sistemi di partito
Abstract

Voce di enciclopedia che fa il punto sulla letteratura teorica ed empirica sui partiti politici

Published
2012

32. Judiciary

Author

GUARNIERI CALBO CROTTA, CARLO ANTONIO, B. BADIE, D. BERG-SCHLOSSER E L. MORLINO, and C. Guarnieri

Subjects
MAGISTRATURA, SISTEMA GIUDIZIARIO, RULE OF LAW, SISTEMA POLITICO, GIUDICE
Abstract

All modern societies tend to entrust the adjudication of disputes arising from the application of recognized norms to a specialized actor, the judge. Collectively, the judges are designed as the judiciary. In some countries – like France and Italy – the judiciary includes also public prosecutors, since they form a unitary organization together with judges. Due to the significance of the adjudication, the judiciary tends to enjoy a special position in most political systems, and especially so in constitutional democracies. Since the middle of the XX century in most political systems the significance of the judiciary has increased, leading to the phenomenon defined as “the judicialization of politics”.

Published
2011

33. Nouveaux acteurs, nouvelle donne

Author

Luizard, Pierre-Jean, Groupe Sociétés, Religions, Laïcités (GSRL), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS), and B. Badie & D. Vidal dir.

Subjects
chiisme, Afghanistan, Irak, Iran, [SHS.HIST]Humanities and Social Sciences/History
Abstract

"Le jeu de l'Iran en Irak et en Afghanistan"

Published
2011

34. Political Culture

Author

CARTOCCI, ROBERTO, B. BADIE D. BERG-SCHLOSSE L. MORLINO, R. Cartocci, and Cartocci, Roberto

Subjects
STATE FORMATION, NATION BUILDING, POLITICAL CULTURE, COMPARATIVE ANALYSIS, SOCIAL CAPITAL
Abstract

Il lemma presenta e discute il concetto di cultura politica e i suoi usi nell'ambito della ricerca empirica, soprattutto nei disegni di ricerca comparati. I paragrafi in cui si sviluppa la voce sono titolati come segue: A new scientific concept and its operational definitions; Change in political culture: the rise of post-materialist values; The limits of the Comparative survey approach; Social capital and democracy;Political culture, nation building, and state formation; Two necessary components of political culture.

Published
2011

35. Cleavages: Social and Political

Author

BARTOLINI, Stefano, B. Badie, Berg-Schlosser, Morlino L., and BARTOLINI S.

Subjects
CLEAVAGE, DIVISIONI SOCIALI E POLITICHE
Abstract

The term cleavage identifies social and political divisions characterized by a close connection between individuals' positioning in the social stratification system, their beliefs and normative orientations, and their behavioral patterns. This close connection contributes to the resilience and stability of cleavages over time. In this entry, the constitutive elements of this concept are discussed and brought into a coherent overall framework that helps illuminate the political relevance of such cleavages.

Published
2011

36. Les politiques énergétiques entre sécurité et défi climatique

Author

Criqui, Patrick, Revel, Danièle, B. Badie et D. Vidal, Laboratoire d'Economie de la Production et de l'Intégration Internationale (LEPII), and Centre National de la Recherche Scientifique (CNRS)-Université Pierre Mendès France - Grenoble 2 (UPMF)

Subjects
POLITIQUE ENERGETIQUE, POLITIQUE CLIMATIQUE, POLITIQUE ENERGETIQUE,POLITIQUE CLIMATIQUE,SECURITE, [SHS.ECO]Humanities and Social Sciences/Economics and Finance, SECURITE, [SHS.ECO] Humanities and Social Sciences/Economics and Finance
Abstract

draft du texte : Notes de travail LEPII ; 6/2009.; Le modèle énergétique sur lequel se sont développées les sociétés industrielles au cours des deux derniers siècles semble parvenu à ses limites. Il n'est en effet ni généralisable à l'ensemble des habitants de la planète ni soutenable dans le temps, compte-tenu des contraintes de ressources et des risques encourus du fait de l'injection dans l'atmosphère de quantités croissantes de CO2. Le XXIe siècle marquera donc une rupture et les sociétés modernes sont confrontées à un défi majeur qui, de tous les problèmes environnementaux, va nécessiter les transformations les plus profondes en matière de technologies, de systèmes de production et de modes de consommation.

Published
2009

37. Les inégalités sociales dans les villes américaines

Author

Body-Gendrot, Sophie, Centre de recherches sociologiques sur le droit et les institutions pénales (CESDIP), Ministère de la Justice-Université de Cergy Pontoise (UCP), Université Paris-Seine-Université Paris-Seine-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Centre National de la Recherche Scientifique (CNRS), Université Paris-Sorbonne (UP4), B. Badie, D. Vidal, and Passegué, Isabelle

Subjects
[SHS.SOCIO]Humanities and Social Sciences/Sociology, [SHS.SOCIO] Humanities and Social Sciences/Sociology
Published
2009

38. L'Europe gagnée par la politique de la peur ?

Author

Body-Gendrot, Sophie, Passegué, Isabelle, B. Badie, S. Tolotti, Centre de recherches sociologiques sur le droit et les institutions pénales (CESDIP), Ministère de la Justice-Université de Cergy Pontoise (UCP), Université Paris-Seine-Université Paris-Seine-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Centre National de la Recherche Scientifique (CNRS), and Université Paris-Sorbonne (UP4)

Subjects
[SHS.SOCIO]Humanities and Social Sciences/Sociology, [SHS.SOCIO] Humanities and Social Sciences/Sociology
Published
2008

39. Les controverses d'égalité en droit en régime républicain. Catégories cognitives et répertoires argumentatifs

Author

Rennes, Juliette, Institut Marcel Mauss (IMM), École des hautes études en sciences sociales (EHESS)-Centre National de la Recherche Scientifique (CNRS), B. Badie, Y. Déloye, and Braunstein, Guillaume

Subjects
catégories, arguments, [SHS.SOCIO]Humanities and Social Sciences/Sociology, [SHS.SOCIO] Humanities and Social Sciences/Sociology, république, sociologie, égalité, droit
Published
2007

40. Agricultural trade liberalization: prospects for developing and developed countries

Author

Bureau, Jean-Christophe, ProdInra, Migration, B. Badie (Directeur), B. Didiot (Directeur), Economie Publique (ECO-PUB), and Institut National de la Recherche Agronomique (INRA)-Institut National Agronomique Paris-Grignon (INA P-G)

Subjects
PAYS EN DEVELOPPEMENT, [SHS] Humanities and Social Sciences, [SHS]Humanities and Social Sciences
Abstract

National audience; Un accord dans le cadre du cycle de négociations de l'Organisation mondiale du commerce se traduirait par des gains globaux, mais assez modestes et inégalement partagés. Parmi les gagnants potentiels, on trouve l'Union européenne, malgré des effets négatifs pour ses producteurs, et de grands exportateurs comme le Brésil. Parmi les perdants potentiels les économies insulaires qui dépendent d'exportations préférentielles de sucre et de bananes.

Published
2006

41. La déterritorialisation des multinationales: firmes globales et firmes-réseaux

Author

Andreff, Wladimir, Réformes et Ouverture des Systèmes Economiques post-Socialistes (ROSES), Université Paris 1 Panthéon-Sorbonne (UP1)-Centre National de la Recherche Scientifique (CNRS), and B. Badie, M.-C. Smouts

Subjects
industria relocation, foreign direct investment, globalisation, [SHS.ECO]Humanities and Social Sciences/Economics and Finance, multinational enterprise, networking enterprise
Published
1996

42. Single-Cell Transcriptomics Sheds Light on Tumor Evolution: Perspectives from City of Hope's Clinical Trial Teams.

Author

Cosgrove PA, Bild AH, Dellinger TH, Badie B, Portnow J, and Nath A

Abstract

Tumor heterogeneity is a significant factor influencing cancer treatment effectiveness and can arise from genetic, epigenetic, and phenotypic variations among cancer cells. Understanding how tumor heterogeneity impacts tumor evolution and therapy response can lead to more effective treatments and improved patient outcomes. Traditional bulk genomic approaches fail to provide insights into cellular-level events, whereas single-cell RNA sequencing (scRNA-seq) offers transcriptomic analysis at the individual cell level, advancing our understanding of tumor growth, progression, and drug response. However, implementing single-cell approaches in clinical trials involves challenges, such as obtaining high-quality cells, technical variability, and the need for complex computational analysis. Effective implementation of single-cell genomics in clinical trials requires a collaborative "Team Medicine" approach, leveraging shared resources, expertise, and workflows. Here, we describe key technical considerations in implementing the collection of research biopsies and lessons learned from integrating scRNA-seq into City of Hope's clinical trial design, highlighting collaborative efforts between computational and clinical teams across breast, brain, and ovarian cancer studies to understand the composition, phenotypic state, and underlying resistance mechanisms within the tumor microenvironment.

Published
2024
Full Text
View/download PDF

43. An intracerebral microdialysis study to determine the neuropharmacokinetics of eribulin in patients with metastatic or primary brain tumors.

Author

Eroglu Z, Synold T, Badie B, Liu A, Chowdhury A, Kilpatrick J, Blanchard S, and Portnow J

Subjects
Adult, Aged, Female, Humans, Male, Middle Aged, Antineoplastic Agents pharmacokinetics, Antineoplastic Agents administration & dosage, Blood-Brain Barrier metabolism, Brain metabolism, Tandem Mass Spectrometry methods, Brain Neoplasms drug therapy, Brain Neoplasms secondary, Brain Neoplasms metabolism, Furans pharmacokinetics, Furans administration & dosage, Ketones pharmacokinetics, Ketones administration & dosage, Microdialysis methods
Abstract

Purpose: Eribulin is an inhibitor of microtubule dynamics. It is not as highly protein bound as the taxanes and is less vulnerable to extrusion by P-glycoprotein in the blood-brain barrier (BBB). These features predict that eribulin could play an active role in managing brain tumors. Indeed, the small amount of published clinical data indicates eribulin may have some efficacy against breast cancer brain metastases. To better understand the potential of eribulin for treating brain tumors, we performed an intracerebral microdialysis study to determine the neuropharmacokinetics of eribulin in cancer patients undergoing tumor resection., Methods: After tumor removal, two microdialysis catheters were inserted into peritumoral brain tissue. Approximately 24 h after surgery, a single dose of eribulin 1.4 mg/m 2 was administered intravenously. Dialysate samples were collected continuously for 72 h, with plasma samples collected in parallel. Eribulin concentrations were analyzed by tandem mass spectrometry., Results: Dialysate samples from 12 intracerebral microdialysis catheters placed in 7 study participants were included in the analysis. A statistically significant difference was observed between eribulin concentrations in brain tissue where BBB was disrupted versus intact, with a difference in mean maximum concentrations on log 2 scale of 3.37 (std err = 0.59, p-value = 0.005). Nonetheless, overall brain to plasma ratios of eribulin only ranged from 0.13 to 1.99%., Conclusion: Although we could detect higher concentrations of eribulin in brain tissue where BBB was disrupted, intracerebral eribulin levels were not sufficient to predict eribulin would have consistent clinically meaningful activity against tumors in the brain., Gov Identifier: NCT02338037 (January 9, 2015)., Competing Interests: Declarations Conflict of interest The authors have no conflicts of interest to declare that are relevant to the content of this article. Ethical approval The clinical protocol for this non-therapeutic study was approved by the City of Hope Institutional Review Board. Consent to participate Written informed consent was obtained from all study participants., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

44. Towards a Robotically Steerable Laser Ablation Probe.

Author

Ceja JA, Rezaeian S, Vélez-Cordero JR, Hernández-Cordero J, Badie B, and Sheng J

Abstract

In this paper, we present a robotically steerable laser ablation probe with application to interstitial thermal therapy. Existing laser interstitial thermal therapy (LITT) methods utilize a straight probe to deliver laser energy around the tip or to the side of the tip. These methods are inadequate to provide effective treatment for large, irregularly shaped tumors. Our robotic probe can be manipulated inside soft tissue to perform ablation at multiple locations, thus enabling conformable ablation for large and complicated tumors. Instead of directly firing laser into soft tissue, a Polydimethylsiloxane (PDMS)/Carbon nanoparticles (CNPs) mixture hosts a multi-mode optical fiber at the probe tip to work as a heater when laser is activated to improve the procedural safety. This paper presents the design and fabrication of the robotic ablation probe, simulation of laser thermal transformation using finite element analysis, and experimental studies that characterize the robot motion and heating effects and demonstrate in vitro ablation.

Published
2024
Full Text
View/download PDF

45. A novel HLA-DQB2::MET gene fusion variant in lung adenocarcinoma with prolonged response to tepotinib: a case report.

Author

Dias E Silva D, Mambetsariev I, Fricke J, Babikian R, Dingal ST, Mazdisnian F, Badie B, Arvanitis L, Afkhami M, Villalona-Calero M, and Salgia R

Abstract

Background: MET rearrangements are infrequently observed in non-small cell lung cancer (NSCLC). Advanced genomic detection techniques have unveiled such infrequent genomic variations, particularly MET fusions in approximately 0.5% of NSCLC patients. Tyrosine kinase inhibitors (TKIs) have revolutionized the standard of care in lung cancer and more recently a second generation MET TKI tepotinib received Food and Drug Administration (FDA) approval for MET exon 14 alterations in metastatic NSCLC. Despite this, the therapeutic landscape for MET -rearranged NSCLC patients remains significantly unexplored. The aim of our report is to detail a unique case of a patient with metastatic lung adenocarcinoma with a novel HLA-DQB2::MET fusion detected by next-generation sequencing (NGS) following previous treatment resistance., Case Description: A 73-year-old female was initially started on carboplatin, pemetrexed and pembrolizumab with maintenance, but eventually had progression in the left upper lobe (LUL). Upon progression she was enrolled in a clinical trial of a monoclonal antibody with or without a PD-1 inhibitor, but brain metastasis progression was eventually detected by magnetic resonance imaging (MRI) requiring stereotactic radiosurgery (SRS) and a craniotomy. The trial drug was eventually discontinued due to progression and toxicity and NGS on bronchoscopy tissue revealed HLA-DQB2::MET fusion. The patient was initiated on tepotinib and continues with clinical and radiological stable disease for over 12 months. The patient's response to a MET inhibitor, tepotinib, underscores the potential efficacy of selective MET inhibitors for individuals with previously unexplored MET fusions., Conclusions: The positive response to tepotinib of a patient with NSCLC harboring a novel MET -Fusion underscores the importance of the use of comprehensive next-generational sequencing-based panels and highlights the necessity for additional research and clinical exploration of selective MET inhibitors for managing NSCLC with MET rearrangements., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-34/coif). The authors have no conflicts of interest to declare., (2024 Translational Lung Cancer Research. All rights reserved.)

Published
2024
Full Text
View/download PDF

46. Author Correction: Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial.

Author

Brown CE, Hibbard JC, Alizadeh D, Blanchard MS, Natri HM, Wang D, Ostberg JR, Aguilar B, Wagner JR, Paul JA, Starr R, Wong RA, Chen W, Shulkin N, Aftabizadeh M, Filippov A, Chaudhry A, Ressler JA, Kilpatrick J, Myers-McNamara P, Chen M, Wang LD, Rockne RC, Georges J, Portnow J, Barish ME, D'Apuzzo M, Banovich NE, Forman SJ, and Badie B

Published
2024
Full Text
View/download PDF

47. Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial.

Author

Brown CE, Hibbard JC, Alizadeh D, Blanchard MS, Natri HM, Wang D, Ostberg JR, Aguilar B, Wagner JR, Paul JA, Starr R, Wong RA, Chen W, Shulkin N, Aftabizadeh M, Filippov A, Chaudhry A, Ressler JA, Kilpatrick J, Myers-McNamara P, Chen M, Wang LD, Rockne RC, Georges J, Portnow J, Barish ME, D'Apuzzo M, Banovich NE, Forman SJ, and Badie B

Subjects
Humans, Neoplasm Recurrence, Local, T-Lymphocytes, Immunotherapy, Adoptive adverse effects, Immunotherapy, Adoptive methods, Receptors, Chimeric Antigen, Glioma therapy, Glioblastoma therapy
Abstract

Chimeric antigen receptor T cell (CAR-T) therapy is an emerging strategy to improve treatment outcomes for recurrent high-grade glioma, a cancer that responds poorly to current therapies. Here we report a completed phase I trial evaluating IL-13Rα2-targeted CAR-T cells in 65 patients with recurrent high-grade glioma, the majority being recurrent glioblastoma (rGBM). Primary objectives were safety and feasibility, maximum tolerated dose/maximum feasible dose and a recommended phase 2 dose plan. Secondary objectives included overall survival, disease response, cytokine dynamics and tumor immune contexture biomarkers. This trial evolved to evaluate three routes of locoregional T cell administration (intratumoral (ICT), intraventricular (ICV) and dual ICT/ICV) and two manufacturing platforms, culminating in arm 5, which utilized dual ICT/ICV delivery and an optimized manufacturing process. Locoregional CAR-T cell administration was feasible and well tolerated, and as there were no dose-limiting toxicities across all arms, a maximum tolerated dose was not determined. Probable treatment-related grade 3+ toxicities were one grade 3 encephalopathy and one grade 3 ataxia. A clinical maximum feasible dose of 200 × 10 6 CAR-T cells per infusion cycle was achieved for arm 5; however, other arms either did not test or achieve this dose due to manufacturing feasibility. A recommended phase 2 dose will be refined in future studies based on data from this trial. Stable disease or better was achieved in 50% (29/58) of patients, with two partial responses, one complete response and a second complete response after additional CAR-T cycles off protocol. For rGBM, median overall survival for all patients was 7.7 months and for arm 5 was 10.2 months. Central nervous system increases in inflammatory cytokines, including IFNγ, CXCL9 and CXCL10, were associated with CAR-T cell administration and bioactivity. Pretreatment intratumoral CD3 T cell levels were positively associated with survival. These findings demonstrate that locoregional IL-13Rα2-targeted CAR-T therapy is safe with promising clinical activity in a subset of patients. ClinicalTrials.gov Identifier: NCT02208362 ., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

48. Expansion of endogenous T cells in CSF of pediatric CNS tumor patients undergoing locoregional delivery of IL13R〿2-targeting CAR T cells: an interim analysis.

Author

Wang L, Oill AT, Blanchard M, Wu M, Hibbard J, Sepulveda S, Peter L, Kilpatrick J, Munoz M, Stiller T, Shulkin N, Wagner J, Dolatabadi A, Nisis M, Shepphird J, Sanchez G, Lingaraju C, Manchanda M, Natri H, Kouakanou L, Sun G, Oliver-Cervantes C, Georges J, Aftabizadeh M, Forman S, Priceman S, Ressler J, Arvanitis L, Cotter J, D'Apuzzo M, Tamrazi B, Badie B, Davidson T, Banovich N, and Brown C

Abstract

Outcomes for pediatric brain tumor patients remain poor, and there is optimism that chimeric antigen receptor (CAR) T cell therapy can improve prognosis. Here, we present interim results from the first six pediatric patients treated on an ongoing phase I clinical trial (NCT04510051) of IL13BBζ-CAR T cells delivered weekly into the lateral cerebral ventricles, identifying clonal expansion of endogenous CAR-negative CD8 + T cells in the cerebrospinal fluid (CSF) over time. Additionally, of the five patients evaluable for disease response, three experienced transient radiographic and/or clinical benefit not meeting protocol criteria for response. The first three patients received CAR T cells alone; later patients received lymphodepletion before the first infusion. There were no dose limiting toxicities (DLTs). Aside from expected cytopenias in patients receiving lymphodepletion, serious adverse events possibly attributed to CAR T cell infusion were limited to one episode of headache and one of liver enzyme elevation. One patient withdrew from treatment during the DLT period due to a Grade 3 catheter-related infection and was not evaluable for disease response, although this was not attributed to CAR T cell infusion. Importantly, scRNA- and scTCR-sequence analyses provided insights into CAR T cell interaction with the endogenous immune system. In particular, clonally expanded endogenous CAR - T cells were recovered from the CSF, but not the peripheral blood, of patients who received intraventricular IL13BBζ-CAR T cell therapy. Additionally, although immune infiltrates in CSF and post-therapy tumor did not generally correlate, a fraction of expanded T cell receptors (TCRs) was seen to overlap between CSF and tumor. This has important implications for what samples are collected on these trials and how they are analyzed. These initial findings provide support for continued investigation into locoregionally-delivered IL13BBζ-CAR T cells for children with brain tumors., Competing Interests: Statement of Competing Interests C.E.B., S.J.P., and S.J.F. report personal fees, patent royalties, and research support from Mustang Bio. C.E.B., S.J.F., and B.B. also have a patent for CAR T cell delivery pending and with royalties paid from Mustang Bio. N.E.B. receives compensation from DeepCell. S.J.P. is also a scientific advisor and/or receives royalties from Imugene Ltd, Bayer, Adicet Bio, and Celularity. Additional Declarations: Yes there is potential Competing Interest. C.E.B., S.J.P., and S.J.F. report personal fees, patent royalties, and research support from Mustang Bio. C.E.B., S.J.F., and B.B. also have a patent for CAR T cell delivery pending and with royalties paid from Mustang Bio. N.E.B. receives compensation from DeepCell. S.J.P. is also a scientific advisor and/or receives royalties from Imugene Ltd, Bayer, Adicet Bio, and Celularity.

Published
2023
Full Text
View/download PDF

49. A Telescopic Tendon-Driven Needle Robot for Minimally Invasive Neurosurgery.

Author

Rezaeian S, Badie B, and Sheng J

Abstract

This paper presents the design, characterization, and testing of a steerable needle robot for minimally invasive neurosurgery. The robot consists of a rigid outer tube and two telescopic tendon-driven steerable tubes. Through the rotation, translation, and bending of individual tubes, this telescopic tendon-driven needle robot can perform dexterous motion and follow the path of the tip. We presented the design of the needle robot and its actuation system, modeling of the robotic kinematics, characterization of the robot motion, results of the open-loop kinematic control, and demonstration of the follow-the-leader motion. The position error of the robot tip is 0.92 mm, and follow-the-leader motion error is 1.1 mm. Due to its small footprint and unique motion ability, the robot has the potential to be manipulated inside human brain and used for minimally invasive neurosurgery.

Published
2023
Full Text
View/download PDF

50. Crosstalk between autophagy and metabolic regulation of (CAR) T cells: therapeutic implications.

Author

Panahi Meymandi AR, Akbari B, Soltantoyeh T, Hadjati J, Klionsky DJ, Badie B, and Mirzaei HR

Subjects
Humans, Autophagy, Cross Reactions, Lysosomes, Tumor Microenvironment, Leukemia, Receptors, Chimeric Antigen
Abstract

Despite chimeric antigen receptor (CAR) T cell therapy's extraordinary success in subsets of B-cell lymphoma and leukemia, various barriers restrict its application in solid tumors. This has prompted investigating new approaches for producing CAR T cells with superior therapeutic potential. Emerging insights into the barriers to CAR T cell clinical success indicate that autophagy shapes the immune response via reprogramming cellular metabolism and vice versa. Autophagy, a self-cannibalization process that includes destroying and recycling intracellular components in the lysosome, influences T cell biology, including development, survival, memory formation, and cellular metabolism. In this review, we will emphasize the critical role of autophagy in regulating and rewiring metabolic circuits in CAR T cells, as well as how the metabolic status of CAR T cells and the tumor microenvironment (TME) alter autophagy regulation in CAR T cells to restore functional competence in CAR Ts traversing solid TMEs., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Panahi Meymandi, Akbari, Soltantoyeh, Hadjati, Klionsky, Badie and Mirzaei.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results